Tri Chemical Laboratories Inc. FY2027 Q2 Earnings Report

Quick View

Executive Summary

Against the backdrop of expanding demand for high-purity chemical compounds used in semiconductor manufacturing, the company delivered a high-quality earnings performance characterized by higher revenue, higher profits, and an improved operating margin. Revenue was ¥147.1B (up +18.8% YoY), Operating Income was ¥38.4B (up +20.8%), Ordinary Income was ¥45.3B (up +19.1%), and Net Income attributable to owners of the parent was ¥33.7B (up +21.5%). The operating margin improved by approximately 40bp YoY to 26.1%, indicating the emergence of operating leverage as profit growth outpaced revenue growth.

Factors Affecting Earnings

【Revenue】The company operates a single business supplying high-purity chemical compounds for semiconductor manufacturing. Driven by expanding demand, Revenue increased to ¥147.1B, representing growth of +18.8% YoY. As the company has a single business segment, factors contributing to changes by segment have not been disclosed.

【Profit and Loss】Operating Income was ¥38.4B (up +20.8%), while the operating margin improved to 26.1%, supported by a gross margin of 36.2% and an SG&A ratio of 10.1% (down from approximately 10.4% in the same period of the previous year). Ordinary Income was ¥45.3B, with the ¥6.9B difference from Operating Income primarily attributable to equity in earnings of affiliates of ¥6.5B, which accounted for the majority of non-operating income (¥7.4B). Net Income was ¥33.7B, with income taxes of ¥11.5B and an effective tax rate of approximately 25.5%, both at normal levels. The company achieved higher revenue and profits, and the profit growth rate exceeded the revenue growth rate, indicating favorable earnings quality.

Segment Analysis

The company operates a single segment comprising the high-purity chemical compounds business for semiconductor manufacturing and does not disclose performance by segment.

Key Financial Indicators

【Profitability】The company maintained high profitability, with an operating margin of 26.1%, a net profit margin of 22.9%, and an EBITDA margin of 34.4%. The gross margin was 36.2%, reflecting a high-value-added product mix.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥48.8B, reaching 1.45 times Net Income of ¥33.7B. OCF/EBITDA was 0.97 times and the accrual ratio was negative 3.1%, indicating strong cash support for reported earnings.【Investment Efficiency】ROE was 8.8%, decomposed into a net profit margin of 22.9% × total asset turnover of 0.30 times × financial leverage of 1.28 times. The asset-intensive business structure depresses total asset turnover and constrains ROE relative to the net profit margin. Annualized DIO was 149 days and CCC was 177 days, indicating room to improve working capital efficiency, with work-in-process inventory accounting for 40.2% of total inventory.【Financial Soundness】The Equity Ratio was 77.9%, the current ratio was 437.3%, the D/E ratio was 0.28 times, and Debt/EBITDA was 0.96 times, representing an extremely conservative financial structure. Despite proceeding with large-scale capital investment, the company retains substantial financial capacity.

Cash Flow Analysis

Operating Cash Flow was ¥48.8B, increasing +78.8% from ¥27.3B in the same period of the previous year and demonstrating cash generation exceeding Net Income of ¥33.7B. Contributing factors included a positive ¥11.1B change in consumption taxes and other items, as well as depreciation and amortization of ¥12.1B. Conversely, an increase in inventories of ¥2.5B and a decrease in accounts payable of ¥6.5B were sources of working capital outflows. Investing Cash Flow was negative ¥29.8B, with the majority represented by capital expenditures of ¥29.7B, indicating capacity expansion investment equivalent to 2.45 times depreciation and amortization. Financing Cash Flow was positive ¥8.6B, primarily due to ¥24.0B in proceeds from long-term borrowings, which financed part of the capital investment. Free Cash Flow remained positive at ¥19.0B, demonstrating that the company maintained its ability to generate internal funds even during a period of expanded investment.

Earnings Quality

The majority of current-period profit was derived from recurring earnings from the core business, and no extraordinary gains or losses were disclosed, suggesting that temporary factors were limited. Ordinary Income of ¥45.3B exceeded Operating Income of ¥38.4B by ¥6.9B, primarily due to equity in earnings of affiliates of ¥6.5B, which constituted the majority of non-operating income of ¥7.4B. The fact that non-operating income equaled 5.1% of Revenue indicates that a certain portion of Ordinary Income depends on the performance of equity-method affiliates. Comprehensive Income was ¥32.4B, slightly below Net Income of ¥33.7B, primarily due to a negative ¥1.9B in other comprehensive income related to equity-method affiliates. The divergence between Net Income and Comprehensive Income was limited. Since Operating Cash Flow reached 1.45 times Net Income and the accrual ratio was negative 3.1%, accounting earnings were supported by cash generation, and earnings quality is considered generally favorable.

Earnings Forecasts and Guidance

Progress against the full-year company forecast was 49.8% for Revenue, 51.5% for Operating Income, 51.9% for Ordinary Income, and 51.3% for Net Income, all slightly above the standard first-half progress benchmark of 50%. The full-year forecast calls for Revenue of ¥295.0B (up +23.5% YoY), Operating Income of ¥74.5B (up +26.2%), and Ordinary Income of ¥87.2B (up +23.0%), reflecting a plan that incorporates higher revenue and profit growth in the second half than in the first half. The earnings forecast was revised during the current quarter, and semiconductor market conditions, customers’ capital investment trends, and the operating status of expanded production facilities will be key factors determining progress in the second half.

Shareholder Returns

As of the end of Q2, the interim dividend was ¥0 per share, while the full-year annual dividend forecast is ¥35.0 per share. Based on forecast EPS of ¥202.17, the Payout Ratio is approximately 17.3%. The total annual dividend is estimated at approximately ¥11.4B based on the number of shares outstanding, remaining within first-half Free Cash Flow of ¥19.0B. Share repurchases were immaterial (0.0B), and capital returns effectively consist primarily of dividends. Given the company’s strong Operating Cash Flow generation and conservative financial structure, the sustainability of the current dividend level appears favorable.

Risk Factors

1. Business concentration risk: The company operates a single business involving high-purity chemical compounds for semiconductor manufacturing. Semiconductor capital investment cycles and fluctuations in customers’ operating rates could directly affect Revenue and facility utilization rates.

2. Working capital and inventory risk: Annualized DIO of 149 days, CCC of 177 days, and a work-in-process inventory ratio of 40.2% indicate high levels of inventory and working capital tied up. During periods of slowing demand, this could lead to inventory valuation losses or additional capital constraints.

3. Investment recovery risk: Capital expenditures amount to ¥29.7B, representing capacity expansion investment equivalent to 2.45 times depreciation and amortization. If start-up delays or shortfalls in expected utilization rates occur, the investment recovery period could be pushed back. In addition, equity in earnings of affiliates of ¥6.5B contributes to Ordinary Income, meaning fluctuations in investees’ performance may amplify changes in Ordinary Income.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability significantly exceeds the industry median and ranks among the top performers.

Growth and Capital Efficiency

Revenue growth also significantly exceeds the industry median, and the pace of revenue growth is at a superior level within the industry.

※Source: Company calculations

Key Points from the Earnings Results

1. The company achieved Revenue growth of +18.8% and Operating Income growth of +20.8%, with profit growth outpacing revenue growth, while the operating margin improved to 26.1%. Together with a gross margin of 36.2%, this demonstrates progress in realizing the benefits of a high-value-added product mix and fixed-cost absorption.

2. Operating Cash Flow was 1.45 times Net Income, and the accrual ratio was negative 3.1%, indicating that current-period profit was supported by cash generation. Meanwhile, DIO of 149 days, CCC of 177 days, and a work-in-process inventory ratio of 40.2% are points to monitor in terms of working capital management during a period of growth investment.

3. Progress toward the full-year forecast was 51.5% for Operating Income, just above the first-half benchmark of 50%. The fact that the plan, premised on a high revenue growth rate in the second half, remains unchanged is a point to verify alongside the operating status of production facilities.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥1,456–¥1,545 at Cost of Equity ±1%, and ¥1,491–¥1,512 at ω±0.1.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market stock price or a recommendation of any specific investment action, and does not predict or guarantee future stock prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q2 was a strong first-half result, with double-digit sales and profit growth, sustained exceptional margins, and cash generation that fully funded elevated investment. Revenue rose 18.8% YoY to ¥14.71bn. Operating income increased 20.8% to ¥3.84bn, slightly outpacing revenue growth. Net income attributable to owners rose 21.5% to ¥3.37bn, and EPS reached ¥103.81. The operating margin expanded by 40bp YoY to 26.1%, from approximately 25.7% in the prior-year period. The gross margin was 36.2%, supporting the view that pricing, product mix, and production economics remained favorable despite ongoing capacity investment. SG&A expenses declined 3.2% YoY to ¥1.49bn while sales grew 18.8%, evidencing substantial operating leverage. EBITDA increased to ¥5.05bn and the EBITDA margin was a high 34.4%. Ordinary income of ¥4.53bn exceeded operating income by ¥0.69bn, supported principally by ¥0.65bn of equity-method earnings. This affiliate-income contribution is meaningful, accounting for roughly 14% of ordinary income, and should be assessed alongside the core operating result. Cash conversion was strong: operating cash flow was ¥4.88bn, or 1.45x net income, while the accruals ratio was negative 3.1%. Free cash flow remained positive at ¥1.90bn after ¥2.97bn of capital expenditure, despite investment spending running at 2.45x depreciation. The balance sheet remains highly liquid, with a 437.3% current ratio and net cash even after long-term borrowing increased. Management has revised its full-year forecast, and first-half progress is broadly in line with the revised plan: 49.8% for sales, 51.5% for operating income, and 51.3% for net income. The main operational watchpoint is manufacturing working-capital intensity, as the quality alerts indicate 149 inventory days, a 177-day cash conversion cycle, and work in process equal to 40.2% of inventory. Overall, the results demonstrate strong demand and execution in high-purity chemicals for semiconductor manufacturing, but the investment case remains sensitive to semiconductor capital-spending cycles, inventory conversion, affiliate earnings, and the return on current capacity expansion.

Profitability Analysis

The reported annualized ROE was 17.6%, an excellent level and above the 15% benchmark. Under the three-factor DuPont framework, annualized ROE comprises a 22.9% net profit margin, 0.599x asset turnover, and 1.28x financial leverage. The principal driver of returns is therefore profitability rather than balance-sheet leverage: the company earns an unusually high margin while using conservative financial leverage. The 26.1% EBIT margin and 34.4% EBITDA margin demonstrate strong operating economics for a specialty semiconductor-materials manufacturer. Margin quality improved, with operating margin expanding 40bp YoY as operating income growth of 20.8% exceeded sales growth of 18.8%. SG&A declined to ¥1.49bn from ¥1.54bn in the prior-year period, creating meaningful operating leverage rather than the adverse pattern of overhead growth exceeding sales growth. The five-factor bridge also supports low financing risk: the tax burden was 0.745, while the interest burden was 1.179 because non-operating income exceeded interest costs and lifted pre-tax income above EBIT. Interest expense was only ¥0.05bn, resulting in 77.59x EBIT interest coverage and 102.13x EBITDA interest coverage. Ordinary income benefited materially from ¥0.65bn in equity-method earnings, so the operating margin is the cleaner indicator of core earnings capacity. Asset turnover of 0.599x is reasonable in the context of a manufacturing balance sheet with PPE equal to 35.2% of assets and a major growth investment program. The sustainability of current returns will depend on utilization and yields at expanded facilities, continued high-purity chemical demand, and whether the elevated inventory cycle converts to sales and cash without margin pressure.

Growth Assessment

First-half revenue growth of 18.8% and operating-income growth of 20.8% indicate that growth remained profitable rather than being purchased through price concessions or a heavier overhead base. The company operates a single business segment focused on high-purity chemical compounds for semiconductor and related manufacturing, concentrating both its technology exposure and end-market sensitivity. Gross profit increased 12.9% YoY to ¥5.33bn, while lower SG&A enabled faster growth in operating profit. EBITDA of ¥5.05bn exceeded operating income by ¥1.21bn, consistent with a capital-intensive production model and increasing depreciation associated with facility investment. CapEx was ¥2.97bn, equivalent to 20.2% of first-half revenue and 2.45x depreciation, indicating capacity expansion rather than maintenance-only spending. The revised full-year sales forecast is ¥29.50bn, implying first-half progress of 49.8%, essentially in line with the standard 50% midpoint. Operating-income progress is 51.5%, 1.5 percentage points ahead of the midpoint, while net-income progress is 51.3%, 1.3 points ahead. These modestly favorable progress rates do not by themselves indicate a material deviation from the revised forecast. Achieving the full-year plan requires second-half revenue of ¥14.80bn and operating income of ¥3.61bn, slightly below the first-half run rate. The full-year forecast calls for sales growth of 23.5% and operating-income growth of 26.2%, so execution in the second half must preserve profitability while supporting a stronger full-year growth trajectory. Continued capacity commissioning, customer qualification timing, and semiconductor production investment will determine whether the high CapEx program translates into sustained incremental revenue.

Financial Health

Financial health is robust. Current assets of ¥24.44bn exceeded current liabilities of ¥5.59bn by ¥18.86bn, producing a 437.3% current ratio and a 431.0% quick ratio. Cash and deposits were ¥10.08bn, equal to 20.5% of total assets and comfortably above the ¥4.87bn of long-term loans. Total equity was ¥38.25bn and represented a 77.9% capital adequacy ratio, while liabilities accounted for only 22.1% of assets. Debt-to-equity was conservative at 0.28x, debt-to-capital was 11.3%, and debt-to-EBITDA was 0.96x. These metrics indicate no material refinancing or solvency strain, and there is no current-ratio or D/E warning threshold breach. Long-term loans increased ¥1.79bn, or 57.9% YoY, to ¥4.87bn; however, the increase appears manageable given the net-cash position, strong operating cash generation, and growth CapEx of ¥2.97bn. Current portions of long-term loans were ¥0.91bn, which are readily covered by cash and broader current assets, limiting maturity-mismatch risk. Cash increased ¥2.80bn YoY to ¥10.08bn, despite the investment program. Accounts payable declined ¥0.65bn, or 31.6% YoY, to ¥1.40bn, reducing supplier-financing support but not creating liquidity pressure. Investment securities of ¥6.61bn represented 13.5% of total assets, making market-value movements and capital-allocation discipline relevant to book-value volatility. The limited intangible asset base of ¥0.10bn, or 0.2% of assets, means the balance sheet is not materially exposed to goodwill or intangible-asset impairment risk.

Notable B/S Changes

Inventories: -¥1.08bn (-75.3%) to ¥0.35bn - the reported decline supported first-half operating cash flow, but elevated 149-day DIO and 40.2% WIP ratio indicate that production-cycle efficiency remains a key monitoring issue. Long-term loans: +¥1.79bn (+57.9%) to ¥4.87bn - borrowing increased during a high-CapEx period, but leverage remains conservative at 0.28x D/E and 0.96x debt/EBITDA. Cash and deposits: +¥2.80bn (+38.4%) to ¥10.08bn - cash accumulation despite ¥2.97bn of CapEx reinforces liquidity and preserves funding flexibility. Accounts payable: -¥0.65bn (-31.6%) to ¥1.40bn - lower supplier financing modestly increases working-capital funding needs, though liquidity remains ample. Investment securities: +¥0.47bn (+7.7%) to ¥6.61bn - securities represent 13.5% of assets, leaving equity and comprehensive income exposed to valuation movements.

Cash Flow Quality

Cash-flow quality was high in the first half. Operating cash flow of ¥4.88bn exceeded net income of ¥3.37bn by ¥1.50bn, yielding an OCF/net-income ratio of 1.45x and clearing the 1.0x high-quality benchmark. Cash conversion, measured as OCF/EBITDA, was 0.97x, also indicating that EBITDA translated effectively into operating cash. The negative 3.1% accruals ratio is favorable and does not suggest profit being supported by aggressive accrual recognition. Operating cash flow benefited from a ¥2.49bn inventory decrease and a ¥0.35bn decrease in trade receivables. These sources of cash should be monitored because the manufacturing efficiency indicators still flag 149 days of inventory and a 177-day cash conversion cycle. The HIGH_INVENTORY_DAYS alert is significant because a 149-day DIO is above the 90-day warning threshold and raises the risk of cash being tied up in production materials, product awaiting qualification, or slower-moving stock if demand weakens. In this specialty chemical industry, inventory may be necessary to ensure supply reliability and support customer qualification cycles, but the level remains elevated relative to the stated benchmark. The LONG_CCC alert reflects the combined burden of inventory and customer collection timing; at 177 days it is well above the 120-day warning threshold, increasing sensitivity of cash flow to production schedules and shipment timing. The HIGH_WIP_RATIO alert, with WIP at 40.2% of inventory, is marginally above the 40% warning level and may indicate longer manufacturing lead times or a production bottleneck. This is particularly relevant for high-purity semiconductor chemicals, where batch processing, stringent quality assurance, and customer certification can lengthen conversion periods. Operating cash flow fully covered ¥2.97bn of CapEx, leaving positive free cash flow of ¥1.90bn. Consequently, current investment is cash-funded at the operating level, although the sustained CapEx intensity means free-cash-flow resilience should be assessed through a semiconductor downcycle rather than extrapolated from one half-year period.

Dividend Sustainability

No interim Q2 dividend was declared. The full-year forecast DPS is ¥35.00, which implies a forecast dividend payout ratio of approximately 17.3% based on forecast EPS of ¥202.17. This is a low payout ratio relative to both earnings and the 60% sustainability benchmark. Forecast cash dividends would be approximately ¥1.14bn using 32.50 million issued shares, below first-half free cash flow of ¥1.90bn. The planned dividend therefore appears well covered by internally generated cash even after the current high level of capital expenditure. Share repurchases were immaterial, so the dividend payout ratio is the relevant shareholder-return measure rather than a total return ratio. The conservative payout is consistent with retaining capital for production capacity, working capital, and technology investment. Dividend sustainability is supported by low leverage, substantial cash balances, and very high interest coverage. The principal constraint on dividend growth is not current affordability but management's capital-allocation preference for semiconductor-related expansion and the cyclicality of customer investment demand.

Risk Assessment

Business risks include Semiconductor cycle risk: the single-segment high-purity chemical business is exposed to wafer-fab utilization, customer qualification schedules, and global semiconductor capital-expenditure volatility., Inventory and production-cycle risk: the HIGH_INVENTORY_DAYS alert of 149 days and HIGH_WIP_RATIO alert of 40.2% indicate a long production conversion cycle; lower demand or delayed customer acceptance could raise obsolescence, write-down, and cash-lockup risk., Customer concentration and qualification risk: specialty materials typically require rigorous qualification, which can delay revenue recognition and make replacement of lost customer volumes difficult., Chemical manufacturing risk: raw-material availability, purity/yield control, plant safety, environmental regulation, contamination incidents, and product-quality failures can disrupt operations and impair customer relationships., Capacity-expansion execution risk: CapEx of ¥2.97bn, or 2.45x depreciation, requires successful commissioning and utilization to earn appropriate returns..

Financial risks include Working-capital risk: the LONG_CCC alert of 177 days is above the 120-day warning threshold, creating sensitivity of operating cash flow to inventory release, receivable collection, and production timing., Affiliate-income exposure: equity-method earnings of ¥0.65bn accounted for roughly 14% of ordinary income, adding earnings sensitivity to investee performance outside core consolidated operations., Investment-security valuation risk: ¥6.61bn of investment securities, equal to 13.5% of total assets, can introduce other comprehensive income and book-value volatility., Borrowing increased 57.9% YoY to ¥4.87bn, although debt service risk remains low given net cash, 0.96x debt/EBITDA, and 102.13x EBITDA interest coverage..

Key concerns include The inventory-days warning is the highest near-term operational concern because DIO of 149 days materially exceeds the 90-day warning benchmark., The 177-day cash conversion cycle warrants close monitoring; it is inconsistent with an otherwise strong cash-flow profile if inventory reductions cannot be sustained., WIP representing 40.2% of inventory suggests potential process, qualification, or production-throughput constraints and should be tracked against shipment growth and gross margin., The full-year forecast assumes continued strong growth and requires preservation of high margins during a heavy investment phase..

Investment Implications

Key takeaways include First-half sales, operating income, and net income grew 18.8%, 20.8%, and 21.5% YoY, respectively, with operating margin expanding to 26.1%., Annualized ROE of 17.6% is driven primarily by a 22.9% net margin rather than financial leverage, supported by a conservative 0.28x D/E ratio., Cash earnings are strong: OCF/net income was 1.45x, OCF/EBITDA was 0.97x, and free cash flow was positive at ¥1.90bn after elevated CapEx., The company is investing for growth, with CapEx at 2.45x depreciation, while retaining substantial liquidity and a net-cash balance-sheet position., The principal counterweight to strong profitability is manufacturing working-capital efficiency, particularly the 149-day DIO, 177-day CCC, and 40.2% WIP ratio..

Metrics to watch include Second-half revenue and operating-income delivery versus the revised ¥29.50bn and ¥7.45bn full-year forecasts, Operating margin and gross margin as new capacity is brought online, Inventory days, WIP proportion, cash conversion cycle, and any inventory write-downs, Operating cash flow and free cash flow relative to the sustained growth-CapEx program, CapEx utilization, depreciation growth, and return on incremental invested capital, Equity-method earnings contribution and investment-security valuation movements, Full-year DPS delivery versus the ¥35.00 forecast.

Regarding relative positioning, The company exhibits a high-return specialty-materials profile, combining a 26.1% operating margin, 17.6% annualized ROE, net cash, and strong interest coverage. Relative to conventional capital-intensive manufacturers, profitability and balance-sheet resilience are notably strong; relative to best-in-class semiconductor-material suppliers, the main areas requiring continued proof are scalable capacity utilization and tighter working-capital conversion.